Introduction
The 13 th World Vaccines Congress was held in Lyon, France on October 16 th -18 th 2012. In the session on New Technologies in Emerging Markets, the scientifi c challenges and opportunities in developing novel vaccines for the emerging and developing markets was discussed by Dr. Danilo Casimiro, Director Vaccines Discovery, Merck Research Laboratories, USA.
New Vaccine Targets
There are numerous new vaccine targets which exisit in different patient populations. These include:
• Pediatric -Group A streptococcal meningitis (ACYW,B), pediatric combinations, respiratory syncytial virus and parainfl uenza virus (RSV/PIV), enterovirus 71 (EV71).
• Adolescent -Chlamydia trachomatis, cytomegalovirus, herpes simplex virus (HSV), epstein-barr virus (EBV).
• Adults -Pneumococcus, cancer, improved infl uenza, alzheimer's disease, anti-cholesterol, Staphylococcus Aureus.
• Elderly/others populations -Bacterial diarrheas, universal infl uenza, clostridium diffi cile, chikungunya, HIV, tuberculosis, malaria. 
Enabling Technologies and R&D Models for Vaccine Development
Examples of these include:
• Protein expression systems -An increasing number of cell substrates are becoming available for heterologous protein expression for human vaccine development which would lead of a decreased cost. 4 • Novel technology -Examples include Pichia strains engineered to express selected human glycosylation molecules (MerckGlycoFi), plant production of vaccines (Medicago, Fraunhofer have developed a tobacco plant based H5N1 fl u vaccine), glycoengineered E. coli (GlycoVaxyn is a biopharmaceutical company Dengue is a highly endemic disease transmitted by the Aedes aegypti mosquito. An approximately 2.5 billion population is at risk and it leads to approx. 50 million cases and 15,000 deaths per year throughout the tropics and subtropics. It is caused by any one of 4 related viruses which are transmitted by mosquitoes. 9, 10 There are no preventative vaccines or antiviral therapies that are currently available. The Dengue vaccines under development include those from • Sanofi Pasteur (ChimeriVax) in Phase III development. It is a live attenuated chimeric virus based on Yellow Fever (YF17D) backbone. Its strengths include decades of experience, established infrastructure to support Phase III trials and demonstrated safety and immunogenicity in Phase II trials. Its weaknesses include recent lack of effi cacy against DEN 2 in a Phase II trial in Thailand and the dosing schedule of 3 doses at 6 mo interval required for tetravalent immunity is not ideal for endemic regions or travelers.
• NIH Partners: Butantan, Biological E in Phase 1 development. This is tetravalent live attenuated viruses with molecularly defi ned mutations including deletions in 3'UTR and chimeras using the DEN4 backbone. Extensive preclinical and clinical testing of each vaccine virus has been done to identify the best candidates and there is a strong partnership with Johns Hopkins for clinical studies. The weakness includes the same basic approach as ChimeriVax and the NIH partnering strategy which is nonexclusive with various partners.
• Inviragen in Phase I development. These are tetravalent live attenuated viruses, which are chimeras using the DEN2 PDK53 backbone. It is supported by NIH/CDC and access to endemic areas will be via Duke/NUS. The weakness is that this is the same approach as ChimeriVax.
• Merck /HBI in Phase I development. This is a tetravalent recombinant env subunit vaccine. There is a native antigen, shorter dosing schedule compared with live attenuated vaccines, no prM protein hence a lower risk of enhancement by anti-prM antibodies and a safety profi le which is well suited to travelers. The weakness is the potential need for a novel adjuvant.
• GSK, WRAIR and FioCruz (Brazil) in preclinical development. This is a purifi ed inactivated virus (PIV) adjuvanted with the GSK adjuvant systems. There is no viral interference, a shorter dosing schedule compared with live attenuated vaccines and a safety profi le well suited to travelers. The weakness is the need for a novel adjuvant, low yields/high cost of goods and the formalin inactivation of the virus will destroy epitopes, which could result in increased risk of Dengue Hemorrhagic Fever.
Recombinant Subunit Dengue Vaccines
Recombinant subunit dengue vaccines (e.g., the Merck/HBI vaccine), 11 have the advantages of: • Shorter dosing schedule compared with live attenuated virus vaccines. They could be easily integrated into the existing vaccination schedules.
• Non-replicating vaccine, hence the safety profi le would allow administration to infants, elderly, pregnant women and immunocompromised subjects.
utilizing its proprietary recombinant DNA technology to develop and manufacture the next-generation of bioconjugate vaccines).
• Adjuvants -These are helpful to increase the response rates and magnitude of the immune responses, simplify the immunization regimen, improve the vaccine response in immunologically impaired populations, improve the durability of the protective effi cacy of vaccines, modify immune responses and enhance the quality of functional antibodies. 5 Many novel adjuvants target Toll-like receptors (TLRs) 6 [e.g., GSK Adjuvant System (AS)] but some have less defi ned mechanisms of action e.g., Saponins, Complete Freund's Adjuvant (CFA01).
However, current US trends in the licensure of new products containing novel adjuvants indicate continuing challenges to vaccine developers.
• Vaccine presentation/delivery -There are numerous innovative Vaccine Delivery devices. Some examples include-Needle free devices (including those developed by Bioject), Microneedle devices (e.g developed by Nanopass 
Novel Vaccine Programs
Examples of novel vaccine programs include those for mosquitoborne human viral diseases, diseases of poverty e.g., HIV and Malaria and Public-Private Partnerships in Vaccine R&D.
Mosquito-Borne Human Viral Diseases
Examples of Mosquito-Borne Human Viral Diseases include • Flaviruses: e.g., Dengue, Yellow Fever, Japanese Encephalitis, West Nile virus.
• Alphaviruses: e.g., Chikungunya, Ross River fever virus, Venezuelan Equine Encephalitis virus, Eastern Equine Encephalitis virus, Western Equine Encephalitis virus.
The Dengue and Chikungunya vaccine development are discussed below.
Dengue Vaccine
earlier stages of malaria infection. This approach targets a region of CSP important to a critical function of the protein. By blocking this function, it is hoped that invasion of the parasite into the liver, an essential step in causing malaria, can be prevented. CSP has already been shown to have protective effi cacy in the fi eld, in RTS,S, the most advanced malaria vaccine candidate.
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MSD-Wellcome Trust Hilleman Laboratories
This leverages on the basic research innovations in academia, government, non-governmental organizations and the industry. It builds on Merck's experience in vaccine bioprocess, formulation and analytics and Wellcome's experience in biomedical research for global health. It provides a fl exible approach to the management of late development, manufacturing and marketing/sales.
The lab is expected to establish linkages among discovery, development and delivery experts. Merck and external scientists would work on the target leads, they would be transitioned to the Hilleman Labs for early development (lead -Phase I) and to multi-national Pharmaceutical manufacturers and low cost manufacturers for late stage development (Phase II -Filing), large scale manufacturing, marketing and distribution.
Conclusion
Vaccines have had and continue to have a huge positive impact on human health and economic development, but there are still many unmet public health threats posed by infectious diseases. Both new and traditional technologies have roles for developing new vaccine candidates and there are numerous vaccines in research and development that utilize these approaches. Recent models for partnerships in the fi ght against global diseases like HIV, TB, Malaria and Dengue not onlwy provide sustained engagement of private and public sectors but also enable the development and delivery of innovative approaches in vaccine R&D.
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• The balance of immunogenicity of the four vaccine components is more easily adjusted and there is the relative ease of changing components of the multivalent vaccine compared with the live virus approaches.
• There is no prM (the DEN-2 PDK-53 structural gene) present in the vaccine formulation. This could possibly reduce the risk of adverse events associated with anti-prM antibodies.
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Merck's Dengue Vaccine
This is against Dengue 1, 2, 3 and 4. The antigen is the Envelope (E) proteins of Dengue 1, 2, 3, and 4 produced in Drosophila S2 cells. The adjuvant used is Saponin (Iscomatrix). The vaccine is in Phase I trials and the protection is mediated by neutralizing antibodies to all 4 types.
Merck's HIV Vaccine
Merck has a long history of developing antivirals and vaccines against HIV-1. The recombinant Adeno 5 (rAd5) competent HIV-1 vaccine (1999-2007) showed lack of effi cacy in the Phase IIb STEP trial. There are multiple vector approaches in pre-clinical and clinical stages. These include:
• HIV Env gp41 fusion intermediate mimetics with highly conserved sequences. This has the potential for broad neutralizing activity and inhibition of dendritic cell mediated HIV-1 transinfection in the acute phase. 13 • Production of HIV Env proteins using Mercks' glycoengineered Pichia strains.
Merck's Malaria Vaccine Program
This program (2010-present) is a collaboration between Malaria Vaccine Initiative (MVI) (the funding partner, responsible for project oversight and management), the NYU Langone Medical Centre (responsible for in vivo studies and biological assays) and Merck (responsible for antigen design, antigen production and carrier conjugation and formulation).
The circumsporozoite protein (CSP) has been recognized as a potential target in the development of vaccines focused on the
